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BACKGROUND: The B-MaP-C study aimed to determine alterations to breast cancer (BC) management during the peak
transmission period of the UK COVID-19 pandemic and the potential impact of these treatment decisions.
METHODS: This was a national cohort study of patients with early BC undergoing multidisciplinary team (MDT)-guided treatment
recommendations during the pandemic, designated ‘standard’ or ‘COVID-altered’, in the preoperative, operative and post-operative
setting.
FINDINGS: Of 3776 patients (from 64 UK units) in the study, 2246 (59%) had ‘COVID-altered’ management. ‘Bridging’ endocrine
therapy was used (n= 951) where theatre capacity was reduced. There was increasing access to COVID-19 low-risk theatres during
the study period (59%). In line with national guidance, immediate breast reconstruction was avoided (n= 299). Where adjuvant
chemotherapy was omitted (n= 81), the median benefit was only 3% (IQR 2–9%) using ‘NHS Predict’. There was the rapid adoption
of new evidence-based hypofractionated radiotherapy (n= 781, from 46 units). Only 14 patients (1%) tested positive for SARS-CoV-
2 during their treatment journey.
CONCLUSIONS: The majority of ‘COVID-altered’ management decisions were largely in line with pre-COVID evidence-based
guidelines, implying that breast cancer survival outcomes are unlikely to be negatively impacted by the pandemic. However, in this
study, the potential impact of delays to BC presentation or diagnosis remains unknown.
British Journal of Cancer (2021) 124:1785–1794; https://doi.org/10.1038/s41416-020-01234-4
BACKGROUND
COVID-19 impact in the United Kingdom
The first case of the novel coronavirus SARS-CoV-2 (coronavirus
disease 2019, COVID-19) was confirmed in the United Kingdom on
January 30, 2020.1 As of August 4, 2020, COVID-19 has resulted in
17,918,582 confirmed cases and 686,703 deaths worldwide since its
emergence in December 2019.2 Globally, the COVID-19 pandemic
has significantly impacted healthcare delivery, including alterations
in cancer care. On 16th March, the UK’s lockdown response was
initiated in response to the United Kingdom reaching ‘Alert Level 4’
(transmission high or rising exponentially), with advice against ‘non-
essential’ travel, social distancing and guidance on self-isolation.3
On 17th March, NHS England announced that all non-urgent
operations in England would be postponed from 15th April to free
up 30,000 beds.4 The ‘Alert Level 4’ subsided on 8th May, with the
relaxation of the ‘stay at home’ message.
Management of breast cancer in the United Kingdom
There are 55,200 new breast cancer diagnoses per year, which
represents 15% of all cancers diagnosed in the United Kingdom.5
Multi-modality treatment, including surgery, radiotherapy (RT) and
systemic therapy, involves multiple hospital visits increasing the
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potential risk of exposure to COVID-19. With current treatments,
early breast cancer prognosis is usually excellent.5,6 Compromises
to cancer care during the COVID-19 pandemic as a result of
rationalisation of resources and prioritisation of individual
patient’s cancer versus COVID-19 risks have the potential to
impact on survival, as well as the quality of life (QoL), service
provision and health economics.
Guidelines for the management of breast cancer during the
COVID-19 pandemic
Multidisciplinary UK guidelines, as well as several European and
American guidelines, were published early in the alert phase,
informing management of breast cancer during the pandemic
(Supplementary Tables 1 and 2).7–13 All aimed to assist rationalisa-
tion and prioritisation of delivery of breast services whilst
healthcare resources were limited and hospitals were considered
a high-infection risk environment. The majority of recommenda-
tions did not deviate substantially from pre-COVID National
Institute for Health and Care Excellence (NICE) national guidance.6
Guidance emphasised multidisciplinary management, balancing
the risk of COVID-19 infection during treatment and the burden of
the COVID-19 pandemic on re-structured health services7 to
enable the delivery of cancer care whilst safeguarding resources
for patients with COVID-19 infection.
When theatre capacity was compromised, guidelines included
the use of preoperative, or ‘bridging’, endocrine therapy (ET)14 and
priority-driven management based on tumour biology10,13,15
(Supplementary Table 1) with the postponement of non-urgent
surgery. Advice included reserving neoadjuvant chemotherapy
(NACT)13 for non-operable disease only, careful consideration of
the risk/benefit of chemotherapy and streamlined use of adjuvant
radiotherapy (RT),16 including potential omission of breast or
nodal radiotherapy or use of five-fraction radiotherapy (5F RT). The
FAST-Forward trial results, published on April 28, 2020, demon-
strated non-inferiority for local recurrence for 5F RT compared to
the UK standard of care of 15 fractions (15F) and with improved
early and similar late normal tissue toxicity,17 providing evidence
for oncologically appropriate RT delivery in a reduced number of
visits. There was a move towards creating ‘green’ operating
capacity, defined as an operating theatre intended to be COVID-19
free (e.g., theatres geographically separate from patients treated
for COVID-19, only doing elective cases with preperative negative
SARS-CoV-2 test as a requirement). This is in contrast to a ‘red’ site,
defined as an operating theatre delivering emergency surgery in
hospitals caring for COVID-19 patients or patients without a
preoperative negative COVID test. In the United Kingdom, this
involved either restructuring of hospital facilities or sourcing
operative capacity in the independent sector.
With the aim of minimising surgical complexity, length of stay
and complication risks, and therefore reducing the risk of COVID-
19 infection, immediate breast reconstruction (IBR) was sus-
pended, with delayed reconstruction to be offered once services
returned to normal. In addition, breast units across the United
Kingdom suspended breast screening from March 2020.
Aims and objectives
The aim of the B-MaP-C study was to determine (i) changes to
breast cancer management during ‘UK alert level 4’ of the UK
COVID-19 pandemic (March 16, 2020 to May 8, 2020),6 (ii) the
potential repercussions of these changes to care in terms of
oncological impact, quality of life (QoL) and healthcare costs and
(iii) the impact of a concurrent COVID-19 diagnosis on patients
undergoing treatment for breast cancer.
METHODS
A multicentre national cohort study was conducted in which
consecutive patients with a diagnosis or early breast cancer
undergoing MDT-guided treatment recommendations during the
peak of the COVID-19 pandemic were eligible for inclusion.18 Full
study information is available on bmapc.org. Patients were
identified prospectively by the local participating clinical teams
during the UK’s ‘Alert Level 4’ phase of the COVID-19 pandemic
(defined as 16th March (the commencement of social distancing
recommendations in the United Kingdom) to 8th May [relaxation
of the ‘stay at home’ message]).
Data were collected and managed using REDCap™ electronic
data capture tools hosted at The University of Manchester,19 in
accordance with Caldicott II principles. Each participating unit was
required to register the study locally with their hospital audit
department and obtain local governance approvals prior to the
commencement of data collection. Ethics approval was not
required according to the NHS Health Research Authority online
decision tool (www.hra-decisiontools.org.uk/research/).18
We collected patient demographic data, cancer-specific data
and multidisciplinary treatment recommendations in the pre-
operative, operative and post-operative setting. Patients on NACT
prior to the pandemic could enter the study period at the peri- or
post-operative multidisciplinary team meeting (MDT-M) (Fig. 1),
hence the inclusion of patients having a diagnosis from August 1,
2019. For each management decision, collaborating units
determined whether the decision was ‘standard' (i.e., the same
as would have been made pre-COVID) or ‘COVID-altered', i.e., not
standard management for that unit’s usual practice (even if
standard practice for other units). An example would be if a unit’s
standard practice is to perform axillary node clearance after
positive sentinel node, but during the alert level 4 period, a
patient was recommended no further axillary surgery after
positive sentinel node.18 Hence, any alterations in management
identified were as a direct result of the COVID-19 pandemic,
representing treatment out of the ordinary for that collaborating
unit. This allowed us to reflect the changes caused by the
pandemic, whilst taking into account the background variability of
practice across the United Kingdom. Altered management
decisions were interrogated in more detail and compared to
pre-COVID NICE guidance on breast cancer management6 as well

















































Fig. 1 Study schematic showing the points at which patients may
enter into the study, the number of patients in each group and
the timelines reported in the study. Patients may have ‘standard’
treatment at all stages in their management journey or may have
‘COVID-altered’ treatment. This latter group may have ‘COVID-
altered’ management in the preoperative, operative or post-
operative stage, and may indeed have ‘standard’ management
decision at some stage. Overlapping ovals indicate overlapping
sub-cohorts. ET endocrine therapy, NACT neoadjuvant chemother-
apy, BCS breast-conserving surgery, SM simple mastectomy,
Adj. adjuvant, CT chemotherapy, RT radiotherapy, HER2 human
epidermal growth factor receptor.
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The study was reported in accordance with the STROBE guidelines
for observational studies.21 A pre-specified statistical analysis plan
was approved by the study steering group. The descriptive
analysis examined characteristics of those patients in whom
standard management was followed and those with ‘COVID-
altered’ management. The subsequent descriptive analysis
explored patients’ demographic and clinical characteristics within
each altered management scenario. Continuous variables are
presented by means (standard deviation, SD) or medians
(interquartile range, IQR), categorical variables are presented by
frequency (percentage). Calculations for each categorical variable
were performed following the exclusion of missing values for this
variable only. Non-parametric Mann–Whitney tests were per-
formed to test for differences of medians between groups
separately for each continuous and ordinal variable and Chi-
squared tests for associations between nominal variables. To
understand the national variation in the response to COVID-19,
both in terms of MDT-M decisions and logistic arrangements,
management decisions for the top 10 recruiting units (as
exemplars) were compared. Analyses were computed using Stata
MP (version 16). Where pertinent, the benefit of chemotherapy
(without taking into account bisphosphonate treatment) using the
NHS Predict online tool was calculated.22 Key exemplar healthcare
costs (using unit costs from published databases [NHS Reference
Costs and Supply Chain]) were compared between routine and
‘COVID-altered’ management to estimate potential financial
impacts to the NHS (Supplementary Material).
Data validity
We utilised REDCap’s built-in analysis tools to run tests of data
completeness and consistency. In particular, the ‘phased’ data
collection offered by the study design allowed us to perform
validation checks to ensure consistency of data entry (Supple-
mentary Table 3). Specifically, we calculated the percentage of
concordance as the agreement of phases 1 and 2 of the study18
divided by total cases, for each category of ‘COVID-altered’
management.
RESULTS
There were 3776 patients included in the study from 64 breast
units in the United Kingdom (with rapid data accrual and wide
geographical representation from screening and symptomatic
units and University Teaching Hospitals and District General
Hospitals, Supplementary Fig. 1). Data validity tests showed high
agreement in all fields interrogated, ranging from 95 to 99%
(Supplementary Table 3). Of the patients included, 1530 (41%) had
standard management and 2246 (59%) had ‘COVID-altered’
management at some point within their treatment journey.
Patients with the higher-stage disease were statistically more
likely to have ‘standard’ management (Table 1). Conversely,
screen-detected cancers were more likely to have standard
management, which may be a function of fewer screen-
detected cancers being treated as the study period progressed
(Fig. 2). Patients with ‘COVID-altered’ management had equivalent
ER-positive disease (81%) and HER2-positive disease (12%) when
compared to contemporary national data.23
Breast cancer management decisions altered due to COVID-19:
neoadjuvant treatment
Of the 2216 patients who had MDT-M decisions in the
preoperative setting, 252 patients had omitted (n= 160) or
incomplete (n= 92) NACT. For those 160 patients where the
pandemic resulted in the omission of NACT, the majority (143/156
[92%]) went on to receive ACT.
To allow postponement of surgery, 951 patients had ‘bridging’
ET (defined in the protocol as ‘Patient with hormone receptor-
positive cancer having ‘bridging’ endocrine therapy due to a
potential delay in surgery’), of which the vast majority (708/862,
82%) were postmenopausal (Table 2). Of patients commenced on
ET, 740/774 (96%) were strongly ER-positive (Allred score 7–8),
with only 4/774 (<1%) having a score below 5, and 140/900 (15%)
assessed pre-operatively as node-positive. Although the primary
reason for ‘bridging’ ET is likely due to anticipated reduced theatre
capacity, in some, the decision may have been driven by
comorbidity and increased risk of COVID-19 mortality.
Surgery
Preoperative imaging assessment was altered in 50 patients, for
example with the omission of magnetic resonance imaging to
assess disease extent. Of the 957 patients with altered surgical
recommendations, 589/957 (62%) had breast-conserving surgery
(BCS), 356/957 (37%) had a simple mastectomy and 12/957 (1%)
had a mastectomy with IBR. There were 42 patients who had a
simple mastectomy when BCS was clinically possible (defined in
the protocol as MDT recommendation for simple mastectomy
over BCS influenced by potential unavailability of radiotherapy),






N= 1530 N= 2246 3776
Age (median-IQR) 56 (48–68) 60 (51–70) <0.001 59 (50–69)
Missing 1 4
T (n= 3682)
Tis 119 (8%) 228 (10%) <0.001 347
T1 577 (38%) 981 (45%) 1558
T2 609 (40%) 777 (36%) 1386
T3 159 (11%) 165 (8%) 324
T4 46 (3%) 21 (1%) 67
Missing 20 74
N (n= 3666)
N0/ N1mi 1037 (69%) 1665 (77%) <0.001 2702
N1 318 (21%) 379 (18%) 697
N2 92 (6%) 74 (3%) 166
N3 63 (4%) 38 (2%) 101
Missing 20 90
M (n= 3675)
M0/MX 1493 (99%) 2149 (99%) 0.033 3642
M1 20 (1%) 13 (1%) 33
Missing 17 84
WHO performance status (n= 3731)
0 1215 (80%) 1688 (76%) 0.032 2903
1 187 (12%) 375 (17%) 562
2 76 (5%) 126 (6%) 202
3 36 (2%) 22 (1%) 58
4 6 (0%) 0 (0%) 6
Missing 10 35
Presentation (n= 3716)
Symptomatic 427 (28%) 913 (41%) <0.001 1340
Screen-
detected
1072 (72%) 1304 (59%) 2376
Missing 31 29
T tumour stage, N nodal stage, M metastases, WHO World Health
Organisation.
T, N are pathological TNM, except where patients were having ET/NACT, in
which case TNM is taken from imaging, using T stage based on the largest
reported size from all imaging modalities.
M1= patients who were diagnosed with metastatic disease after surgery.
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likely because breast radiotherapy could not be delivered locally.
This group had a high number of premenopausal patients (13/40,
33%), with high-grade disease (26/41, 63% grade 3) and
disproportionately more ER-negative disease (17/41, 41%)
(Table 2), suggesting that oncological considerations impacted
these decisions. Thirteen patients had change to standard practice
because they had no completion axillary clearance (ANC)
following a positive sentinel node, when ANC at that unit would
have been offered pre-COVID. There is relative clinical uncertainty
around completion ANC in subgroups of patients. For example,
based on pre-COVID advice, all 13 patients were eligible for the
POSNOC study24 where ANC could have been appropriately
omitted. Nine patients also fulfilled Z0011 criteria for the omission
of completion axillary clearance.25
The utilisation of IBR has doubled over the last two decades.26
However, in this cohort, there were 299 patients who were not
offered IBR, when the usual pre-COVID practice would have
included this. These patients were young (median age 50, 61%
premenopausal), reflecting a subgroup where IBR would usually
be considered a priority. The estimated cost of mastectomy and
IBR for these patients would have been £1,636,969, whereas the
total cost of mastectomy plus delayed reconstruction is an
estimated £3,063,428 (an additional cost of £1,426,459; Supple-
mentary Material).
Adjuvant treatment
Of 1863 patients who had a post-operative MDT-M decision, 81
patients had adjuvant chemotherapy omitted, which would have
been offered in the pre-COVID environment, including 13/81
patients with omitted NACT as described above. There were 62/81
patients in whom a decision was made to omit chemotherapy
based on clinical grounds (without genomic testing). This group
had a median benefit of chemotherapy of 3% (IQR 2–9%) using
NHS Predict calculations.22 The majority of patients with omitted
chemotherapy were postmenopausal (61/80, 75%), with no/low
nodal burden (N0 or N1= 77/80, 96%) and ER-positive disease
(59/81, 73%) with one or more comorbidities (80/81, 99%),
implying holistic risk-benefit decision- making (Table 2). Collabor-
ating units were asked to report cases where genomic testing
directly influenced MDT-M recommendation to avoid adjuvant
chemotherapy (that, following NICE guidance, would not usually
have been used pre-COVID). This was the case in 19/81 patients. In
addition, extended-indication genomic testing outside of the 2018
NICE guidelines (such as patients with node-positive disease,
which was outside of NICE guidance),27 was used in 27 patients, of
whom 21 avoided chemotherapy based on genomic test
outcome.
Thirteen patients with HER2-positive disease had no adjuvant-
targeted (anti-HER2) therapy or chemotherapy when standard
management would have included this. The median age of this
group was 73 (range 52–84), with low tumour stage (T1= 5/13, T2
= 7/13), low nodal stage (N0/N1= 11/13) and largely ER-positive
disease (11/13). Four patients with HER2-positive disease received
adjuvant anti-HER2 therapy without systemic adjuvant che-
motherapy, in accordance with COVID-19 guidance.
There were 96 patients in whom adjuvant radiotherapy was not
recommended, whereas pre-COVID local MDT-M practice would
have been to recommend radiotherapy. We explored the
clinicopathological characteristics of these patients and noted
that of these 96, 45 patients (47%) met inclusion criteria for the
avoidance of radiotherapy based on NICE guidelines6 or the
PRIME2 study.28 In line with the time guidelines for 5F breast and
chest wall RT12 and the FAST-Forward publication, 781 patients
had adjuvant radiotherapy with 5F where, pre-COVID, 15F would
have been administered (Table 2). Of 64 units included in this
study, 46 (72%) offered the fast-forward radiotherapy protocol,
evidencing the ability to rapidly introduce new clinical practice
based on high-quality trial data. As an exemplar of the potential
positive health economic impact of changes to management, the
cost saving of change to 5 F was investigated. The change from
15F to 5F for these patients is estimated to have saved £1,421,420
(supplementary material). Compared to those having 5F RT, 504
patients receiving 15F were younger (median age 56 years, IQR
49–67 vs 59 years, IQR 53–67, P= 0.006), had larger tumours
(mean size 27.6 mm (1·1) vs 20.3 mm (0.6), P= 0.0000), and higher
nodal burden (mean number of macrometastatic nodes 2.3 (0.2)
vs 0.4 (0.1), P < 0.0001).
Logistic changes to breast surgery during the COVID-19 pandemic
Of 3776 patients, 1778 (47%) had surgery within the study period;
1052 (59%) were in ‘green’ (COVID low-risk) zone operating
theatre and 726 (41%) in ‘red’ (COVID high-risk) theatres. There
was a move towards increasing access to ‘green’ theatres as the
study progressed as units adapted their services in response to the
pandemic, from 51 (29%) operations in the first week to 125 (69%)
operations in the final week of the study (Fig. 3). The median time
to surgery from diagnosis for patients (excluding those on NACT
or ET) was 24 days (IQR 16–34), and was similar in both ‘red’
(25 days, IQR 15–33) and ‘green’ (24 days, IQR 16–34) theatres,
which is within NHS Breast Screening Programme/NICE pre-COVID
targets.
Recommended practice for sentinel lymph node biopsy surgery
is with dual localisation using Technicium-99-m isotope and
Patent blue dye.29 In 122 cases, sentinel node biopsy was
performed with blue dye only. This was more common in ‘green’
theatres that were usually non-NHS independent sector hospitals
(117/122, 96%) versus ‘red’ theatres that were usually NHS acute
care trusts (5/122, 4%).
Breast cancer management decisions: national variation
To get a sense of the variation in practice across the United
Kingdom, we compared changes to normal practice in the ten
units contributing the most patient datasets to the study (totalling
37% of the study cohort), with the frequency of ‘standard’
treatment, use of ‘bridging’ ET and use of five-fraction RT as
exemplars. Within these ten units, the frequency of standard
treatment ranged from 25% to 59%, the frequency of ET from 2%
to 35% and of five fractions of RT from 11% to 51% of each
hospital’s total patient cohort (Fig. 4a). This may highlight local
differences in the ability to access theatre space or to rapidly
implement a new evidence-based practice. There was an increase











































Fig. 2 Change over time in the number of patients presenting
with screen-detected versus symptomatic breast cancer during
the study period. Week 1 begins on 16th March, and week 8 ends
on 8th May.
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N 252c 951c 42c 299c 81c 96c 781c
Agea 52 (28–78) 65 (35–92) 59 (39–77) 50 (28–75) 63 (38–78) 69 (63–77) 59 (53–67)
Menopausal status (n)
Pre/peri-menopausal 121 (50) 154 (18) 13 (33) 176 (61) 20 (25) 13 (15) 187 (26)
Postmenopausal 119 (50) 708 (82) 27 (67) 113 (39) 61 (75) 76 (85) 544 (74)
Missing 12 89 2 10 0 7 50
Tumour stage
Is 0 87 (10) 0 23 (8) 0 16 (17) 46 (6)
1 58 (23) 455 (50) 15 (37) 80 (27) 33 (41) 57 (61) 433 (56)
2 142 (57) 310 (34) 23 (56) 132 (44) 39 (49) 15 (16) 252 (33)
3 40 (16) 50 (6) 2 (5) 58 (20) 6 (8) 4 (4) 40 (5)
4 10 (4) 4 (0) 1 (2) 4 (1) 2 (2) 2 (2) 3 (0)
Missing 2 45 1 2 1 2 7
Nodal stage
0/mi 125 (50) 760 (84) 23 (56) 175 (59) 36 (45) 82 (86) 638 (83)
1 75 (30) 124 (14) 14 (34) 76 (26) 41 (51) 12 (13) 112 (15)
2 33 (13) 10 (1) 4 (10) 32 (11) 3 (4) 1 (1) 15 (2)
3 17 (7) 6 (1) 0 (0) 14 (5) 0 (0) 0 (0) 6 (1)
Missing 2 51 1 2 1 1 10
Metastases
M0 248 (99) 897 (100) 41 (100) 293 (99) 80 (100) 95 (100) 770 (100)
M1 2 (1) 3 (0) 0 (0) 3 (1) 0 (0) 0 (0) 3 (0)
Missing 2 51 1 3 1 1 8
Size MMG/USS MMG/USS MMG/USS MMG/USS Path. Path. Path.
Size in mmb 29·0 (1.2) 20·7 (0.5) 24·2 (2.2) 32·8 (1.5) 27·5 (1.8) 17·8 (1.4) 20·3 (0.6)
28·3 (1.0) 16·9 (0.4) 23·7 (1.9) 23·9 (1.0)
Missing 9/8 34/39 1/1 13/9 1 3 20
Histological type
IDC 226 (92) 599 (65) 39 (95) 207 (71) 65 (82) 65 (71) 548 (72)
ILC 7 (3) 149 (16) 0 (0) 48 (16) 8 (10) 5 (5) 107 (14)
Mixed 4 (2) 31 (3) 1 (2) 9 (3) 3 (4) 1 (1) 26 (3)
Other 9 (4) 54 (6) 1 (2) 6 (2) 3 (4) 5 (5) 40 (5)
DCIS 0 94 (10) 0 232 (8) 0 16 (17) 45 (6)
Missing 6 24 1 6 2 1 15
Grade (invasive)
1 2 (1) 204 (25) 1 (2) 14 (5) 3 (4) 19 (26) 126 (18)
2 67 (27) 507 (62) 14 (34) 147 (54) 42 (53) 43 (58) 407 (57)
3 178 (72) 109 (13) 26 (63) 110 (41) 35 (44) 12 (16) 181 (25)
Missing 5 37 1 5 1 3 67
Grade (DCIS)
LG 0 12 (14) 0 1 (4) 0 0 (0) 0 (0.0)
IG 0 29 (33) 0 5 (23) 0 4 (27) 12 (27)
HG 0 46 (53) 0 16 (73) 0 11 (73) 33 (73)
Missing 0 7 0 1 0 1 0
ER
+ 121 (49) 922 (100) 24 (59) 221 (76) 59 (73) 76 (89) 656 (86)
− 127 (51) 3 (0) 17 (41) 71 (24) 22 (27) 9 (11) 104 (14)
Missing 4 26 1 7 0 8 21
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of ‘bridging’ ET as the study progressed (Fig. 4b), indicating some
recovery in service delivery. In patients commenced on pre-
operative/’bridging’ ET, 210 patients went on to have surgery by
the end of the study. The median length of time of ET for these
patients was 22 days (IQR 15–31). The most common reason for
proceeding with surgery early was unexpected availability of
theatre capacity (53%).
SARS-CoV-2 testing, outcome and impact on patient journey
There were 1392 patients tested for SARS-CoV-2, the majority in
the preoperative setting (1033, 74%). Fourteen patients tested
positive (1%). Of 11 patients testing positive before surgery, all
were managed at home, without need for hospital admission, with
a median time from diagnosis to surgery of 52 days (range
18–168). Those with >90-day delay (n= 2) were temporised with
‘bridging’ NET. There was an increase in preoperative hospital
testing during the study period, no doubt, reflecting the
increasing availability of SARS-CoV-2 tests nationally (Supplemen-
tary Fig. 2). Three patients tested positive post-operatively, of
which two had surgery in a red zone.
There was no SARS-CoV-2-related mortality.
DISCUSSION
The COVID-19 pandemic has had unprecedented effects on
healthcare provision across the United Kingdom. Early reports
from both the United Kingdom and globally have shown that
malignancy was a predictor of mortality30,31 and poor outcomes
from COVID-19.31–33 No previous reports have focused specifically
on alterations of care during the pandemic, to early breast cancer
patients.34 The major challenges during the pandemic have been









































Red zone Green zone
Fig. 3 Transition to ‘green’ (COVID low-risk) theatres. Change over
time during the ‘study period, showing an increase in the number of
























N 252c 951c 42c 299c 81c 96c 781c
PR
+ 78 (33) 620 (85) 19 (48) 160 (63) 48 (66) 51 (72) 462 (71)
− 155 (67) 106 (15) 21 (52) 95 (37) 25 (34) 20 (28) 188 (29)
Missing 19 225 2 44 8 21 221
HER2
+ 116 (47) 63 (8) 8 (20) 71 (26) 21 (26) 3 (4) 85 (12)
− 132 (53) 761 (92) 33 (80) 205 (74) 59 (74) 75 (96) 636 (88)
Missing 4 137 1 23 1 15 60
Ki67b 36·2 (3·6) 18·8 (2·5) 29·6 (5·1) 27·4 (3·4) 24·4 (6·0) 14.6 (2·5) 19.8 (1·6)
Missing 213 847 24 246 65 75 654
Comorbidities
None 6 (2) 46 (5) 1 (2) 6 (2) 1 (1) 4 (4) 19 (2)
≥1 246 (98) 905 (95) 41 (98) 293 (98) 80 (99) 92 (96) 762 (98)
Missing 0 0 0 0 0 0 0
WHO PS
0 197 (79) 667 (71) 28 (67) 261 (87) 63 (78) 61 (64) 658 (85)
1 40 (16) 180 (19) 9 (21) 29 (10) 14 (17) 26 (27) 104 (13)
2 11 (4) 74 (8) 5 (12) 9 (3) 4 (5) 7 (7) 13 (2)
3 2 (1) 13 (1) 0 (0) 0 (0) 0 (0) 2 (2) 2 (0)
4 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Missing 2 17 0 0 0 0 4
NACT neoadjuvant chemotherapy, ET neoadjuvant endocrine therapy, Mx mastectomy, BCS breast-conserving surgery, CT chemotherapy, RT radiotherapy,
IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, DCIS ductal carcinoma in situ, LG low grade, IG intermediate grade, HG high grade, ER
oestrogen receptor, PR progesterone receptor, HER2 Human epidermal growth factor receptor 2, PS performance status.
aMedian (IQR).
bMean (SD).
cPatients could be in more than one category.
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SARS-CoV-2 to patients and healthcare providers, and to admin-
ister treatment in healthcare settings where resources and
capacity are strained. The rapid publication of guidelines by
several organisations7–13,16 facilitated the implementation of
practical evidence-based decisions, as evidenced by the results
of this study.
Despite treatment recorded as ‘COVID-altered’ in 2246 (59%)
patients as per study definitions,18 the vast majority of patients in
this study were treated according to pre-COVID guidelines. Only
439/2246 (19%) patients had a management that was clearly
outside the pre-COVID breast cancer NICE guidelines (omission of
a reconstruction or premenopausal patients on ‘bridging’ ET),
implying that breast cancer oncological outcomes in this study are
unlikely to be negatively impacted (although the psychological
impact of reconstruction omission is yet to be determined). Where
‘COVID-altered’ management plans had to be instigated, these
were mostly within guidelines published during the pandemic.
There is likely, however, to be a cohort of women who are yet to
present, either symptomatically or through screening, with breast
cancer. Their outcomes may be disadvantaged through the late
presentation, although that group lies outside the scope of
this study.
Where theatre capacity has been an issue, there was increased
use of preoperative ET compared to the usual pre-COVID
practice,29 largely as ‘bridging’ therapy.35 Indeed, a large number
of patients initially placed on ‘bridging’ ET in anticipation of
significant surgical delay who have already had surgery, as theatre
capacity, particularly in ‘green’ theatres, has increased. In those
not receiving any neoadjuvant or bridging treatment (n= 1074),
surgery has taken place in a timely manner. This has to be taken in
context with the reduction in a number of patients presenting,
particularly with screen-detected cancer. It is noteworthy that
there were low rates of SARV-CoV-2 infection and no reported
COVID-19-related post-operative deaths.
It is evident that some surgical decisions have reflected local
resource availability for adjuvant therapies. For example, there was
a cohort of patients (n= 42) undergoing simple mastectomy
when pre-COVID practice would have been BCS followed by
adjuvant RT. These patients were younger, with more aggressive
tumour characteristics, and hence this represents, for a short
period of time, a decision to prioritise reduction of recurrence risk,
whilst there was uncertainty over RT availability. We have
identified a large group of patients who have not had IBR when
usual practice would have recommended this. UK NICE guidelines
recommend all women undergoing a mastectomy be offered IBR.6
However, the COVID-19 pandemic has led to the suspension of IBR
in many countries worldwide due to resource, workforce and
safety concerns. This may lead to detrimental effects on the
aspects of QoL such as body image.
Internationally, standard-of-care chemotherapy treatment regi-
mens have been adapted to minimise the intensity of hospital
visits and hospitalisation, and to prevent cancer treatment-
induced complications of COVID-19.7–11,13,15,16,20,36 Transferring
NACT to the adjuvant setting is oncologically safe,37 but may
deprive the patient of the opportunity of downstaging to
accommodate BCS, and prevent identification of nonresponders.
These nonresponders may potentially be deprived of further
adjuvant treatment such as the NICE-approved Trastuzumab
emtansine in patients with HER2-positive disease or Capecitabine
in patients with triple-negative breast cancer. The majority of
patients omitting NACT received adjuvant chemotherapy reflect-
ing the changing scenario during the COVID-19 ‘Alert Level 4’,
where initial apprehension for systemic therapy had subsided by
the time these patients had completed surgery.
In many units, there has been rapid adoption of the results of
the FAST-Forward study, with an almost immediate change to
treatment protocols across the country.38 We categorised 5F RT as
‘altered management’ because the start of the study predated the
5-year local control results of the FAST-Forward study, although
prepublication national guidelines supported the use of 5F based
on 3-year toxicity results of FAST Forward.12 This allowed us to
determine the reactiveness of breast cancer services to new
evidence and guidance issued during the pandemic. The 5F
protocol was advantageous from a service provision perspective,
where at the height of the pandemic, the workforce was greatly
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Fig. 4 National Variations in management of breast cancer during the COVID-19 pandemic. a Variation in management decisions in the
top 10 recruiting units, comparing the percentage of patients with (i) standard management (light grey bar), (ii) bridging ET (grey bar) and
(iii) 5-fraction RT (black bar). b Trends in management decisions during the study period, by date of diagnosis at weekly intervals.
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number of hospital visits and COVID-19 exposure risk. For those
that did not have adjuvant radiotherapy, most were within criteria
for planned avoidance of radiotherapy using NICE guidelines6 and
PRIME228 criteria. Had research trials been available, these patients
may potentially have been recruited into the PRIMETIME study,
which had been temporarily closed during the pandemic.
Inevitably, there are some limitations to a study of this nature,
particularly one executed in such a short time frame. It is
recognised that the data reported in this study have the potential
to be subject to reporting bias, data entry error, and indeed, some
decisions made early in the COVID-19 ‘alert level 4’may have been
subject to change particularly as the peak of the pandemic
subsided. It is also appreciated that the study did not include all
units in the United Kingdom, and not all participating units were
able to collect data on consecutive patients within the study
period, by the study deadline. Nevertheless, this still remains a
representative national picture of the impact of the COVID-19
pandemic on breast cancer treatment in the United Kingdom.
Clinical research is a key component of high-quality breast
cancer care. In the year 2018/19, over 9000 patients were recruited
to breast cancer clinical trials (National Cancer Research Institute
Annual Report 18/19). However, the pandemic has resulted in the
suspension of many clinical trials, with the redeployment of cancer
research staff to allow prioritisation of COVID-19 studies. Across all
cancer sites, only 31% of cancer trials continued as planned during
the pandemic (National Institute for Health Research (NIHR),
personal communication, unpublished data). Although the NIHR
has now published a framework for restarting clinical research,
recovery of trial recruitment is slow. This has implications for
patients in accessing trials and novel treatments, and for
researchers to deliver studies to time and target. The extent of
this impact on the UK breast cancer clinical research portfolio,
however, remains to be elucidated.
Our study has described the extent of changes (and key cost
implications) in the management of breast cancer in the United
Kingdom during the COVID-19 pandemic on a patient and
population-based level, as a response to timely and feasible
guidance that was largely followed at a time of national crisis.
Appraisal of these changes will guide the evaluation of the impact
of the pandemic on immediate patient outcomes and the degree
to which breast cancer management has been affected in routine
clinical practice. This will assist with planning of service delivery
once routine breast cancer management resumes and in the
event of a further pandemic. There are significant implications for
the COVID-19 ‘recovery’ phase with patients on endocrine therapy
requiring cancer resection, and those denied IBR awaiting delayed
breast reconstruction. Anticipating the recommencement of
breast screening, this delayed (or postponed) activity is likely to
overstretch breast surgical services. In the long term, we will have
the opportunity to assess the impact of treatment alterations on
the rate of disease recurrence and overall patient survival, QoL
and the impact of these management decisions on the service
and health economics.
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